Press Release

Harpoon Therapeutics Appoints Ms. Julie Eastland, Biotech Industry Veteran, to Board of Directors

South San Francisco, CA – October 11, 2018 – Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engaging therapeutics, announced today that it has appointed Ms. Julie Eastland to its Board of Directors.

“We are pleased to welcome Ms. Eastland to the Harpoon board. She is a seasoned executive who brings strong financial, operations and business development experience, which will be instrumental as Harpoon continues to advance its immunotherapy product candidates,” said Jerry McMahon, PhD, President and CEO, Harpoon Therapeutics.

“I am pleased to join the distinguished Harpoon board and look forward to supporting the company’s progress as it expands its novel research and development efforts into important clinical programs,” said Ms. Eastland.

Ms. Eastland currently serves as the Chief Financial and Business Officer of BioClin Therapeutics, a private biopharmaceutical company focused in FGFR3 bladder cancer. She previously served as Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, helping negotiate the sale of the company to Seattle Genetics and assisting in the subsequent corporate transition. Prior to Cascadian, she served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

About Harpoon Therapeutics


Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC™), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, and is initially focused on the treatment of solid tumors and hematologic malignancies. For more information, please visit www.harpoontx.com.

Contact

Harpoon Therapeutics
Kinkead Communications, Inc.
Susan Kinkead, +1 415-509-3610
susan@kinkeadcomm.com